nicotinamide mononucleotide + l-leucine

**Nicotinamide mononucleotide + l-leucine** is a combination drug comprising two active ingredients: nicotinamide mononucleotide (NMN), a nucleotide derived from nicotinamide and a direct precursor to NAD+ (nicotinamide adenine dinucleotide), and l-leucine, an essential branched-chain amino acid. NMN is recognized for its role in elevating NAD+ levels, leading to improved mitochondrial function, reduced oxidative stress, and enhanced cellular energy metabolism, particularly relevant in aging, muscle degeneration (sarcopenia), and metabolic dysfunctions[2][3]. L-leucine acts as a key regulator of muscle protein synthesis, supporting energy/glucose metabolism, reducing muscle breakdown, and promoting recovery from muscle degeneration or stress[3]. The combination of NMN and l-leucine is being investigated primarily for potential synergistic effects in therapies targeting **age-related muscle loss (sarcopenia)**, where these compounds may help alleviate oxidative damage, preserve mitochondrial and cytoskeletal integrity, and promote muscle health and recovery. The combination is typically administered in controlled-release systems such as lipid vesicles, but standard oral formulations may also be considered[3].

Other names

nicotinamide mononucleotide + l-leucine